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Edited by Miguel De la RosaAbstract The dendritic cell speciﬁc C-type lectin dendritic cell
speciﬁc ICAM-3 grabbing non-integrin (DC-SIGN) binds to
‘‘self’’ glycan ligands found on human cells and to ‘‘foreign’’ gly-
cans of bacterial or parasitic pathogens. Here, we investigated
the binding properties of DC-SIGN to a large array of potential
ligands in a glycan array format. Our data indicate that
DC-SIGN binds with Kd < 2 lM to a neoglycoconjugate in which
Galb1-4(Fuca1-3)GlcNAc (Lex) trisaccharides are expressed
multivalently. A lower selective binding was observed to
oligomannose-type N-glycans, diantennary N-glycans expressing
Lex and GalNAcb1-4(Fuca1-3)GlcNAc (LacdiNAc-fucose),
whereas no binding was observed to N-glycans expressing core-
fucose linked either a1-6 or a1-3 to the Asn-linked GlcNAc of
N-glycans. These results demonstrate that DC-SIGN is selective
in its recognition of speciﬁc types of fucosylated glycans and sub-
sets of oligomannose- and complex-type N-glycans.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Carbohydrate recognition1. Introduction
The innate immune system provides the ﬁrst line of defense
by detecting the immediate presence of pathogens and deter-
mining the nature of subsequent immune events. Recognition
of invading pathogens by macrophages and dendritic cells
(DCs) is mediated by pattern-recognition receptors (PRR),
including Toll-like Receptors [1] and C-type lectins [2]. C-type
lectins bind carbohydrates in a Ca2+-dependent manner, using
conserved carbohydrate recognition domains (CRDs). The
binding of a glycan to the CRD may depend on more thanAbbreviations: CHO, Chinese hamster ovarian; CRDs, carbohydrate
recognition domain; (i)DCs, (immature) dendritic cells; DC-SIGN,
dendritic cell speciﬁc ICAM-3 grabbing non-integrin; FUT, fucosyl-
transferase; LDN, LacdiNAc; LDNF, LacdiNAc-fucose; Le, Lewis
antigen; PAA, polyacrylamide; PRR, pattern recognition receptor;
RFU, relative ﬂuorescence units; mAb, monoclonal antibody
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doi:10.1016/j.febslet.2006.10.009one monosaccharide and on subtle diﬀerences in the spatial
arrangements of these monosaccharides. C-type lectins con-
taining CRDs with similar monosaccharide selectivity can also
bind their ligands in distinct ways. In addition, oligomerization
of CRD domains may alter the aﬃnity and speciﬁcity of bind-
ing. The diﬀerential expression of many diﬀerent (C-type) lec-
tins in combination with their binding properties, thus create
unique sets of carbohydrate recognition proﬁles on DCs [3,4].
DC-SIGN (dendritic cell-speciﬁc ICAM-3-grabbing non-
integrin; CD209), is a type II transmembrane C-type lectin
with a single C-terminal CRD [5]. The CRD is separated from
the transmembrane region by a neck domain that is thought to
aﬀect the formation of oligomers [6]. DC-SIGN binds to ‘‘self’’
glycan ligands found on human cells [7,8] as well as to ‘‘for-
eign’’ glycans derived from bacterial or parasitic pathogens
[9–11]. The results from several studies using recombinant or
cell surface expressed DC-SIGN, indicate that DC-SIGN typ-
ically recognizes at least two classes of glycans, mannose rich,
and fucosylated glycans [9,12–14].To increase our understand-
ing of the function of DC-SIGN, we report here a detailed and
(semi-)quantitative characterization of the glycan binding
speciﬁcity and properties of DC-SIGN-Fc to more than 100
glycans, including several complex-type N-linked glycans not
tested previously.2. Materials and methods
2.1. Antibodies and cells
Anti-core fucose polyclonal antibodies were obtained as described
previously [15]. The monoclonal antibody (mAb) G8G12 recognizes
Lex [16], mAb SMLDN1.1 recognizes GalNAcb1-4GlcNAc (Lacdi-
NAc, LDN) [17] and mAb SMFG4.1 binds GalNAcb1-4(Fuca1-3)Glc-
NAc (LacdiNAc-fucose, LDNF) glycan antigens [11]. DC-SIGN-Fc
has been described previously [18]. Chinese hamster ovary (CHO) cells
were cultured in RPMI-1640 (Gibco, BRL, USA) with 10% FCS
(BioWithaker, Verviers, Belgium) 100 U/ml penicillin and 100 lg/ml
streptomycin (Pen/Strep). CHO cells stably expressing the Polyoma
virus large T antigen (CHOP2) were kindly provided by Dr. James
Dennis (Toronto, Canada) [19]. CHOP2 cells are deﬁcient in sialic acid
transport, resulting in >90% reduction in sialic acid content [20].
CHOP8 cells derived from CHO glycosylation mutant Lec8 are defec-
tive in UDP-galactose transport, resulting in truncated glycans without
galactose [21]. CHO PIR-P3 cells, were kindly provided by Dr.
Mark Lehrman (Dallas, Texas) [22]. Lec8 cells stably transfected
with Caenorhabditis elegans b1-4-N-acetylgalactosaminyltransferaseblished by Elsevier B.V. All rights reserved.
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transfected with b1-4GalNAcT and fucosyltransferase IX (FUT 9),
expressing poly-LDNF glycans, have been described previously [23].
Where indicated, cells were cultured during 5 days in the presence of
the a-mannosidase-I inhibitor kifunensine (2 lg/ml; Calbiochem,
USA). Eﬃciency of treatment was assessed by ﬂow cytometry analysis
using Concanavalin A AlexaFluor-488 (Molecular probes, Inc.,
Eugene, OR).2.2. Transient transfection and ﬂow cytometry
Cells were incubated until 50–80% conﬂuency. Transfection was per-
formed according to the manufacturer’s protocol. In short, both DNA
and LipofectAMINE (Invitrogen, Carlsbad, CA) were diluted in ser-
um-free medium and combined to allow DNA–liposome complexes
to form and subsequently added to the cells. After 24 h the medium
was replaced with fresh, complete medium. Forty-eight hours after
transfection cells were used for ﬂow cytometry (FACSscan, BD
Pharmingen, San Diego, CA) to detect binding of anti-glycan antibod-
ies and DC-SIGN-Fc in TSM (20 mM Tris–HCl pH 7.4, containing
150 mM NaCl, 2 mM CaCl2 and 2 mM MgCl2) with 0.5% BSA
(TSA), using FITC or AlexaFluor-conjugated anti-human or anti-
mouse secondary antibodies.2.3. Glycosidase treatment of cell-lysates, SDS–PAGE and Western
blotting
Cells were lysed in 50 mM Tris–HCl pH 7.4, containing 0.1%
sodium dodecyl sulfate (SDS) and protease inhibitors. Where indicated
lyophilised lysates were treated by endoglycosidase H (EndoH, recom-
binant Escherichia coli, Boehringer, Mannheim GmbH, Germany) or
a-mannosidase (from Jack Beans, Sigma–Aldrich, St. Louis, MO)
according to the manufacturers protocol. The proteins within the
lysates were separated by SDS–polyacrylamide gel electrophoresis
(SDS–PAGE) on 12.5% gels, using the Mini-Protean III system (Bio-
rad, Hercules, CA) and blotted onto a nitrocellulose membrane
(Schleicher and Schuell, Bioscience Inc., Dassel, Germany). After
blocking the membrane with 5% BSA (Fluka Biochemica) in TSM,
the blots were incubated with DC-SIGN-Fc (5 lg/ml) in TSA, washed
in TSM containing 0.1% Tween-20 (ICN Biomedicals Inc., Aurora,
OH) and incubated with peroxidase-labeled goat-anti-human IgG-Fc
(Jackson, West Grove, PA). Bound DC-SIGN-Fc was detected by
measuring chemiluminescence, using Supersignal WestPico Chemilu-
minescence substrate (Pierce, Rockford, IL), in an Epi Chemi II Dark-
room (UVP bioimaging systems, Upland, CA) and Labworks Software
(UVP, USA).2.4. Fluorescence solid phase glycan array
Streptavidin-coated high binding capacity black plates (Pierce,
Rockford, IL) were washed three times with 200 ll TSM and coated
at saturating densities with biotinylated oligosaccharides, glycopep-
tides or polyacrylamide (PAA) coupled glycoconjugates (20% substi-
tution, Lectinity, Lappeenranta, Finland) in TSA. After washing with
TSM, puriﬁed DC-SIGN-Fc (5 lg/ml in TSA) or an anti-glycan
antibody (to determine coating eﬃciency) was added. Bound DC-
SIGN-Fc was detected after incubation with AlexaFluor-488 goat-
anti-human- or mouse-IgG (5 lg/ml; Molecular Probes) by measuring
ﬂuorescence (FluoStar, BMG Labtech GmbH, Oﬀenburg, Germany).
The assays were performed in triplicate and background ﬂuorescence
was subtracted from each sample. The glycan array screening (ELI-
SA-based) was performed by Core H of the Consortium of Functional
Glycomics. The array used was Version 1.1.a. containing glycan struc-
tures with the CFG numbers (#) 1–89, as described in supplemental
data of Bochner et al. [24]. In addition, a secondary screening was per-
formed with in addition glycans with the CFG # 112, 114, 129–132,
185 and 186, which are described in supplemental data by Coombs
et al. [25]. The structure Bi-Lex was synthesized starting with
desialylated human transferrin, which was fucosylated using recombi-
nant fucosyltransferase VI (Calbiochem, Germany) and GDP-
fucose. All used glycan structures and their CFG numbers, as well as
standard procedures for glycan array testing by the Consortium for
Functional Glycomics are available at http://web.mit.edu/glycomics/
consortium.2.5. Surface plasmon resonance
All surface plasmon resonance (SPR) experiments were performed at
25 C on a Biacore 3000 instrument (Biacore Inc., Piscataway, NJ).
The running buﬀer used was TSM containing 0.005% Tween20. Biotin-
ylated glycans were captured on research grade streptavidin-coated
sensor chips (Sensor Chip SA, Biacore Inc.) that were pretreated with
three 1 min infusions of 1 M NaCl in 50 mM NaOH. A 10 fmol/ll
solution of each biotinylated glycan was injected at 2 ll/min for
7.5 min to capture each glycan on an independent surface. In total,
three diﬀerent glycans and a control (non-binding) glycan, were stud-
ied using one SA sensor chip. Speciﬁc binding of DC-SIGN-Fc to
the test glycans was measured using the in-line reference subtraction
feature of the Biacore 3000 instrument. Increasing concentrations of
DC-SIGN-Fc were injected at a ﬂow-rate of 35 ll/min over all four
surfaces of the sensor chip. The equilibrium binding data of DC-
SIGN-Fc were analysed by non-linear curve ﬁtting of the Langmuir
binding isotherm using the BIAevaluation software (Biacore Inc., Pis-
cataway, NJ).3. Results
3.1. Analysis of the glycan-binding speciﬁcity of DC-SIGN-Fc
by glycan array screening
Binding of the chimeric DC-SIGN-Fc to a total of 100 dif-
ferent glycan structures was analyzed using glycan-array tech-
nology. In these arrays, similar amounts of individual
biotinylated glycans or glycopeptides were immobilized on
streptavidin-coated plates, allowing semi-quantitative binding
analysis (Consortium for Functional Glycomics). The consoli-
dated data of the glycan array are shown in Fig. 1. DC-SIGN-
Fc binds to N-linked oligomannose with the highest apparent
aﬃnity for the structure Man9GlcNAc2, and decreasing bind-
ing apparent aﬃnity as the number of mannoses decreases,
as shown in Fig. 1A. DC-SIGN-Fc shows binding to several
fucosylated glycans. Of the glycans tested, Lewis b (Fuca1-
2Galb1-3(Fuca1-4)GlcNAcb; Leb) shows the highest relative
binding, followed by Lewis y (Fuca1-2Galb1-4(Fuca1-3)Glc-
NAcb; Ley) and Lewis a (Galb1-3(Fuca1-4)GlcNAcb; Lea).
The trisaccharides Lewis x (Galb1-4(Fuca1-3)GlcNAcb; Lex)
and LDNF (GalNAcb1-4(Fuca1,3)GlcNAc) are bound
slightly less eﬃciently, however diantennary N-glycans con-
taining these epitopes (bi-Lex and bi-LDNF) show a 4-fold in-
crease in binding of DC-SIGN-Fc over the terminal
trisaccharides alone (Fig. 1B). The a1-6 core-fucosylated
Man3GlcNAc2 is not bound by DC-SIGN. From these results
it can be concluded that presentation of DC-SIGN glycan li-
gands, such as Lexor LDNF, within a diantennary N-glycan
clearly enhances binding as compared to the individual glycan
determinants.3.2. Binding of DC-SIGN-Fc to multivalent neoglycoconjugates
The binding of DC-SIGN to multivalent glycans was tested
in a similar solid phase assay by using biotinylated polyacryl-
amide (PAA) that is modiﬁed to contain monosaccharides or
fucose- or mannose-containing glycans. By titrating DC-
SIGN-Fc in the binding assays, the IC50 was established, with
the IC50 being the concentration that shows 50% of the max-
imal binding to the diﬀerent PAA–neoglycoconjugates.
Fig. 2A shows the titration curves for some of the glycans
tested. Based on their binding properties, the PAA-linked gly-
cans tested in this assay can be divided into four groups
(Fig. 2B). The ﬁrst group contains neoglycoconjugates carry-
ing Lea or Leb, which show binding even when low concentra-
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Fig. 1. Consolidated data of glycan array. A glycan array was probed with DC-SIGN-Fc (5 lg/ml). After subtraction of the background signal, the
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Neoglycoconjugates containing Lex, Ley, 6-sulfo-Lea and
mannotriose (Mana1,3(Mana1,6)Man) showed binding at
intermediate DC-SIGN concentrations (IC50 between 5 and
7 lg/ml), whereas H-type-2 antigen (Fuca1-2Galb1-4GlcNAc)
and a-L-fucose, showed only a low binding when high DC-
SIGN-Fc concentrations were used (IC 50 between 8 and
15 lg/ml). The last group consists of neoglycoconjugates carry-
ing sialyl-Lex, 6-sulfo-Lex and a-D-mannose, which were not
bound by DC-SIGN-Fc (Fig. 2B).
3.3. DC-SIGN binds to glycan epitopes on the surface of cells
To study the binding of DC-SIGN to cell-surface expressed
glycoconjugates, which more likely represents the natural pre-sentation, the binding capacity of recombinant DC-SIGN-Fc
to CHO cells and CHO-glycosylation mutants was determined
by FACS analysis. The results show that DC-SIGN-Fc does
not bind to wild-type CHO cells or to CHOP2 cells (CHO cells
that carry glycans lacking sialic acid) (Fig. 3). By contrast, low
binding was observed to CHOP8 cells, CHO cells that are deﬁ-
cient in UDP-galactose transport due to a lec8 mutation
(Fig. 3) [21]. These cells express N-glycans with terminal Glc-
NAc, and truncated O-glycans with terminal GalNAc (Tn
antigen). The glycan-array studies described above, as well as
previous studies of others, have shown that oligomannose-type
N-glycans are recognized by DC-SIGN in vitro [26,6,27,28].
To analyze the binding of DC-SIGN to whole cells carrying
oligomannose-type N-glycans on glycoproteins, we cultured
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Fig. 3. Binding capacity of DC-SIGN-Fc to CHO glycosylation mutants. In the left panel, the black histogram shows the binding of DC-SIGN-Fc
(goat-anti-human Alexa Fluor 488) to these cells and the middle panel shows whether the binding is Ca2+-dependent (binding in the presence
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a-mannosidase I, which causes expression of mainly Man9Glc-
NAc2. DC-SIGN-Fc binds very well to CHOP2 cells culturedwith kifunensine, suggesting that oligomannose-type N-gly-
cans on cell-surface expressed proteins are recognized ligands
within the context of cellular expression (Fig. 3). To investigate
CHOP2 cells Mr (kD)
Endo H
75
25
150
100
50
37
Kifunensine
250
Fig. 4. Binding of DC-SIGN-Fc to CHOP2 cells cultured with
kifunensine on Western blot. Cell-lysates were made of CHOP2 cells
cultured with or without kifunensine. Cell-lysates were treated with
endoglycosidases as indicated. The proteins of the lysate were
separated by SDS–PAGE and transferred to a membrane for Western
blotting. The binding of DC-SIGN-Fc to CHOP2 cells cultured with
kifunensine was abolished after treatment with Endo H, indicating that
DC-SIGN-Fc binds to oligomannose-type glycans expressed by
CHOP2 cells.
Transfected inding of Binding of Typical
CHO cells DC-SIGN-Fc anti-glycan N-glycan
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Fig. 5. The binding capacity of DC-SIGN-Fc to CHOP2 cells
transfected with glycosyltransferases. The binding of DC-SIGN-Fc
to CHOP2 cells transfected with cDNAs of glycosyltransferases was
analyzed by ﬂow cytometry. In the left panel, the binding to DC-
SIGN-Fc (secondary antibody goat-anti human Alexa Fluor 488) is
shown in black and non-stained cells are shown as grey lines. In the
second panel, the expression was determined by staining the cells with
a speciﬁc anti-glycan-antibody (goat-anti-mouse Alexa Fluor 488). The
parental CHO cells are all negative in staining with the anti-glycan
antibodies (results not shown). The second and third rows indicate
CHOP2 cells that are transiently transfected with cDNAs encoding for,
respectively, FUT IV and core a1-3-fucosyltransferase (CFT3),
resulting in approx. 35% of the cells being transfected. The fourth
(poly-LDN) and ﬁfth row (poly-LDNF) show stably transfected cells
(100% of the cells expressing the glycosyltransferases). In the right
panel a typical N-glycan structure for each cell is depicted. The arrows
indicate the monosaccharides added by the diﬀerent glycosyltransfe-
rases. Cells were gated on forward and side scatter and the mean
ﬂuorescence of one representative experiment out of three is shown.
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in the presence of kifunensine was indeed dependent on bind-
ing to the oligomannose-type glycans, the cells were lysed and
proteins were separated by SDS–PAGE followed by Western
blotting and binding of DC-SIGN-Fc was detected. No bind-
ing of DC-SIGN-Fc to CHOP2 cells was observed on Western
blots. Analysis of the binding of DC-SIGN-Fc to kifunensine-
treated CHOP2 cells revealed binding to a wide array of glyco-
proteins with apparent Mr between 70 and 120 kD (Fig. 4).
Treatment of the cell-lysate with endoglycosidase H, an en-
zyme that removes oligomannose-type glycans, or alternatively
with a-mannosidase, that cleaves terminal a-linked mannose
residues, abolished binding of DC-SIGN-Fc completely
(Fig. 4, data not shown). This indicates that the oligoman-
nose-type glycans in the cell-lysate are the ligands of DC-
SIGN. CHO-cells PIR-P3, which are resistant to the plant
lectin Phaseolus vulgaris erythroagglutinin primarily express
N-glycans of the Man3GlcNAc2 type (70–75%)[22]. DC-
SIGN-Fc bound well to these CHO PIR-P3 cells, which can
be blocked by EDTA, indicating that the binding is Ca2+-
dependent as would be expected (Fig. 3). In conclusion,
whereas DC-SIGN-Fc does not bind to wild-type CHO cells
or CHOP2 cells, it binds to both oligomannose-type N-linked
glycans or N-glycans with the structure Man3GlcNAc2 on the
cell surface.
3.4. Transfection of speciﬁc glycosyltransferases can induce
the expression of DC-SIGN ligands on CHOP2 cells
To modify the cellular glycans expressed by CHOP2 cells,
the cells were transiently transfected with diﬀerent glycosyl-
transferase cDNAs and the binding of DC-SIGN-Fc to these
cells was analyzed. CHOP2 cells were transfected with the
cDNA of human fucosyltransferase 4 (FUT 4) [29] and Arabid-
opsis thaliana core a1-3fucosyltransferase (C3FT) [30], respec-tively. The expression of the induced glycan antigens and the
binding of DC-SIGN-Fc were determined by FACS analysis.
FUT-4 adds a fucose in an a1-3 linkage to Galb1-4GlcNAc,
generating the Lex epitope (Fig. 5). Using an anti-Lex antibody
it was demonstrated that 35% of the cell population following
transfection carried the Lex epitope. DC-SIGN-Fc binds to the
CHOP2 cell fraction expressing FUT-4 (Fig. 5). C3FT adds a
fucose in a1-3 linkage to the Asn-linked GlcNAc of N-glycans,
thus forming a highly immunogenic glycan epitope such as
found in plant- and insect allergens, as well as in parasitic
helminths [15]. FACS-analysis clearly showed that the core
a1-3fucose is present in 30% of the cells, however no binding
of DC-SIGN-Fc could be detected (Fig. 5). To analyze the
binding of DC-SIGN to LDNF-containing glycoproteins ex-
pressed on the surface of cells, stably transfected CHO cells
expressing either poly-LDN or poly-LDNF glycans [23] were
tested for their ability to bind DC-SIGN-Fc. CHO cells
expressing poly-LDNF glycans showed strong binding of
DC-SIGN-Fc (Fig. 5) in a Ca2+-dependent manner, whereas
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Fig. 6. Binding of DC-SIGN-Fc to bi-LDNF, Man8GlcNAc2 and Le
x–PAA as assessed by surface plasmon resonance (SPR). (A) Speciﬁc binding is
shown of DC-SIGN-Fc to bi-LDNF, Man8GlcNAc2 and Lex–PAA. The SPR-response (in resonance units) versus time (in s) is shown using 6 lM
DC-SIGN-Fc. (B) Aﬃnity of DC-SIGN-Fc binding to Lex–PAA as measured by SPR. The equilibrium SPR response is plotted versus the DC-
SIGN-Fc concentration, using DC-SIGN-Fc concentrations of 0–12 lM. The data were analyzed by non-linear curve ﬁtting and one representative
experiment out of four is shown.
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expressing poly-LDN. These results demonstrate that DC-
SIGN binds to Lex-expressing and LDNF-expressing glycans
on cell surfaces but not to surface glycans lacking these epi-
topes in CHO cells.
3.5. Aﬃnity of DC-SIGN-Fc binding
The binding aﬃnities of DC-SIGN-Fc for Man8GlcNAc2,
bi-LDNF and Lex–PAA biotinylated neoglycoconjugates were
determined by surface plasmon resonance (SPR) using a strep-
tavidin-coated sensor chip. Bi-LDN was captured on one
surface of the sensor chip and used as negative control. DC-
SIGN-Fc showed speciﬁc binding to all three glycans tested
(Fig. 6A). The sensorgram shows that upon injection, the bind-
ing of DC-SIGN-Fc to Lex–PAA neoglycoconjugate slowly
reached equilibrium and the bound DC-SIGN-Fc slowly disso-
ciated after injection was stopped. By contrast, DC-SIGN-Fc
binding to Man8GlcNAc2 and bi-LDNF rapidly reached
equilibrium in the ﬁrst few seconds after injection, and fast
dissociation of the bound DC-SIGN-Fc was observed. The
apparent dissociation constant (Kd) for DC-SIGN-Fc tothe three test glycans was determined in triplicate by varying
the concentration of DC-SIGN-Fc from 0 to 12 lM. For
Lex–PAA the apparent Kd is 1.74 lM (Fig. 6B), whereas the
apparent Kd to Man8GlcNAc2 and bi-LDNF is at least two
times lower than the Kd measured for Le
x–PAA neoglycocon-
jugate (results not shown).4. Discussion
Recent evidence indicates that dendritic cell associated DC-
SIGN may have a dual function in the induction of tolerance
to self-antigens and recognition of pathogens, respectively. Be-
cause the function of dendritic cells may be dependent on their
binding properties to self-antigens and pathogens, it is essential
to obtain detailed insight in the carbohydrate-binding proper-
ties of DC-SIGN. In this report, we describe the glycan-bind-
ing proﬁle of DC-SIGN by determining its binding properties
to a library of glycan structures and glycopeptides on a glycan
array, as well as to glycans expressed multivalently, and
cell-surface expressed glycans. For these studies we used an
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each arm of the IgG chimera, and is therefore bivalent [18].
Using glycan arrays assembled by the Consortium for Func-
tional Glycomics, we showed that DC-SIGN-Fc interacts with
various a1-3 and a1-4 fucosylated tri- and tetrasaccharides,
such as the monovalent Lewis antigens and LDNF, and with
increased aﬃnity to mannose type N-glycans carrying 5–9
mannose residues and diantennary glycans comprising a Lex
or LDNF antigen within each of the branches. Although some
slight diﬀerences are seen, the general conclusion is that the
binding properties of DC-SIGN-Fc are very similar to those
of the renatured tetramer of DC-SIGN, as reported recently
by Guo et al. [13]. In previous studies we already demonstrated
that bivalent DC-SIGN-Fc and natural, cell-surface expressed
DC-SIGN that is understood to be tetrameric [31,28], show
very similar binding properties [9,14]. Together, these data
indicate that DC-SIGN-Fc is a reliable tool to study the bind-
ing properties of DC-SIGN to its glycan ligands.
Using extended glycan arrays from the Consortium of Func-
tional Glycomics and cellular adhesion assays, we show here
for the ﬁrst time that DC-SIGN is able to bind LDNF present
within N-glycans. The diﬀerence in structure between Lex and
LDNF is the N-acetyl group of the GalNAc residue in LDNF.
Apparently, this additional N-acetyl group does not interfere
with DC-SIGN binding, similar to the situation in Ley where
an additional fucose occurs that is linked to the 2 position of
Gal [14]. However, in contrast to the situation for Lewis struc-
tures or LDNF, DC-SIGN is highly speciﬁc for the nature of
the glycans expressing Fuca1-3GlcNAc moieties, since it does
not bind to that structure when it is part of the core structure
of an N-glycan. This may be due to the lack of a GlcNAc
linked Gal or GalNAc that contributes to the binding to the
CRD domain of DC-SIGN and/or spatial interference of the
distal aspects of the N-glycan [13,14]. This lack of binding to
core a1-3-fucose residues indicates that DC-SIGN is not di-
rectly involved in the induction of immune responses to this
glycan epitope or glycotope that have been demonstrated to
occur in plant- and insect induced allergies [32].
The glycan array data indicate that a 4-fold increase in bind-
ing aﬃnity of DC-SIGN-Fc was found towards a diantennary
N-glycan containing Lex (bi-Lex) and a diantennary N-glycan
containing LDNF (bi-LDNF), compared to the respective tri-
saccharide determinants. Considering the bivalent nature of
DC-SIGN-Fc it would in principle be possible that the two
binding sites on each arm of the IgG chimera associate and dis-
sociate from the two Lex/LDNF units of the diantennary gly-
can with the same binding parameters. To test if a multivalent
presentation would increase the aﬃnity even further, we used
SPR to analyze the speciﬁcity and aﬃnity of the binding of
DC-SIGN-Fc to a neoglycoconjugate where Lex is coupled
multivalently to polyacrylamide (Lex–PAA), and compared
the binding properties to those towards bi-LDNF and the oli-
gomannose-type glycan Man8GlcNAc2. The SPR data show
that binding of DC-SIGN-Fc to all three ligands is speciﬁc.
By analysis of the DC-SIGN-Fc data for equilibrium binding
responses, an apparent Kd of 1.7 lM was found towards
Lex–PAA, whereas the apparent Kd for Man8GlcNAc2 and
bi-LDNF was at least 5 lM. Whereas these experiments give
insight in the aﬃnity range of DC-SIGN binding to its ligands,
it should be noted that the data cannot directly be compared
quantitatively, since the polyvalent nature of the ligand Lex–
PAA will introduce avidity eﬀects, whereas Man8GlcNAc2 isa monovalent ligand by contrast. In addition, and in contrast
to the binding pattern to Lex–PAA and Man8GlcNAc2, we
could not determine a consistent binding pattern of DC-
SIGN-Fc to bi-LDNF by SPR. It may be that both DC-SIGN
subunits diﬀerentially interact with the bi-LDNF structure
because the spacing or orientation of both branches does not
allow proper bivalent binding to both LDNF units.
The aﬃnity of DC-SIGN binding in the low lM range (2–
10 lM) to its glycan ligands is in the same range to those found
for other mammalian lectins of biological importance. For
example, both Siglec 8 and galectin 1 bind to their respective
ligands with apparent Kd  2–4 lM [24,33]. In vivo, we pro-
pose that a high degree of glycan binding can be achieved
through tetramerisation of DC-SIGN at the cell surface
[31,28], which for example facilitates binding to oligomannose
glycans as found on HIV-1 [34]. In addition, other pathogens
are strongly recognized by DC-SIGN, which is likely to occur
by combining an intermediate aﬃnity with varying avidity ef-
fects, such as Schistosoma mansoni that expresses both Lex and
LDNF antigens [35]. We show here that DC-SIGN-Fc
strongly binds to mammalian cells engineered to express N-gly-
cans carrying antennae with repeating LDNF units [23], struc-
tures that are indeed found within S. mansoni worms [36].
These LDNF-expressing glycoproteins as well as Lex and pseu-
do-Ley expressing glycoproteins and/or glycolipids found in
schistosomes are expected to be targets of humoral and cellular
immune reponses during schistosome infection, in which DC-
SIGN might play an important role [10,11].
It is becoming increasingly clear that an important aspect of
DC-SIGN binding may also be provided by its potential to
bind with high avidity to glycan ligands that are bound with
very low relative aﬃnity in their monovalent context. In the
glycan array, we showed that DC-SIGN-Fc has no signiﬁcant
aﬃnity to truncated N-glycans (Mana1-3(Mana1-6)Manb1-
2GlcNAcb1- 4GlcNAc-R, Man3). However, signiﬁcant DC-
SIGN-Fc binding was observed to glycosylation mutant cells
expressing mainly Man3GlcNAc2on their cell-surface, or to
Mana1-3(Mana1-6)Man linked to PAA. Similar observations
were obtained with H-type 2 glycans, carrying a a1-2-linked
fucose. Interestingly, it was recently reported that a Neisseria
meningitides LPS oligosaccharide mutant IgtB, which ex-
presses GlcNAcb1-3Galb1-4-Glc-R outer core units, targets
dendritic cells through DC-SIGN, thereby mediating highly
eﬃcient bacterial uptake and skewing of the immune response
into a TH1 direction [37]. Although our current glycan array
data do not reveal GlcNAc as a ligand for DC-SIGN [13],
we show here that DC-SIGN-Fc exhibits binding to the
CHO glycosylation mutant Lec8 that expresses N-glycans car-
rying a terminal GlcNAc on its cell-surface. These data suggest
that DC-SIGN may bind to terminal GlcNAc residues when
they are presented at high density. Since a high density of
repeating glycan moieties is generally lacking on mammalian
cell surfaces or glycoproteins, this feature of DC-SIGN bind-
ing through avidity and possibly clustering of DC-SIGN on
the cell surface [31] may be of particular importance for path-
ogen recognition.
Our data show that DC-SIGN can bind various ligands in
diﬀerent ways, which may have consequences for how the
pathogen or antigen is processed by DCs. Many pathogens ex-
ploit self-glycans or glycans that speciﬁcally target C-type lec-
tins including DC-SIGN to direct the immune response in
favor of their own survival and thus evade host immunity
6130 E. van Liempt et al. / FEBS Letters 580 (2006) 6123–6131[38]. The detailed dissection of molecular interactions between
DC lectins and its glycan ligands as described here will facili-
tate future studies to clarify the role of these lectins in modu-
lation of dendritic cell functions.
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